Management of delayed encephalopathy after CO poisoning: An evidence-based narrative review.

ABSTRACT: BACKGROUND:Approximately 10% to 30% patients develop delayed encephalopathy after acute CO poisoning (DEACMP). No specific treatment is available and poor prognosis is a characteristic of this disease. We aimed to evaluate the efficacy and safety of all therapies that have been tried in randomized controlled trial (RCT) for DEACMP. METHODS:We conducted a systematic search of the Cochrane, Embase, PubMed, and Web of Science databases. RESULTS:Overall, 4 RCTs were identified in our study. Both hyperbaric oxygen (HBO) and mesenchymal stem cell (MSC) transplantation were effective in DEACMP, and MSC seemed to be superior to HBO. The addition of dexamethasone, N-butylphthalide, or XingZhi-YiNao granules into HBO, or butylphthalide into MSC could achieve better neurological recovery in DEACMP pa

SUBMITTER: Xu XM 

PROVIDER: S-EPMC6919536 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature